{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T16:15:06Z","timestamp":1791130506066,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,10,5]],"date-time":"2010-10-05T00:00:00Z","timestamp":1286236800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s00277-010-1090-2","type":"journal-article","created":{"date-parts":[[2010,10,4]],"date-time":"2010-10-04T10:08:01Z","timestamp":1286186881000},"page":"379-387","source":"Crossref","is-referenced-by-count":59,"title":["Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial"],"prefix":"10.1007","volume":"90","author":[{"given":"Myrna","family":"Candelaria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aquileo","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Labardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Gonz\u00e1lez-Fierro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Trejo-Becerril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Taja-Chayeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"P\u00e9rez-C\u00e1rdenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"de la Cruz-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daymi","family":"Arias-Bofill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Due\u00f1as-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,10,5]]},"reference":[{"key":"1090_CR1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ajh.21352","volume":"84","author":"MT Kasner","year":"2009","unstructured":"Kasner MT, Luger SM (2009) Update on the therapy for myelodysplastic syndrome. Am J Hematol 84:177\u2013186","journal-title":"Am J Hematol"},{"key":"1090_CR2","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood.V90.4.1403","volume":"4","author":"T Uchida","year":"1997","unstructured":"Uchida T, Kinoshita T, Nagai H, Nakahara Y, Saito H, Tota T (1997) Hypermethylation of the p15\/INK4B gene in myelodysplastic syndromes. Blood 4:1403\u20131409","journal-title":"Blood"},{"issue":"Suppl 2","key":"1090_CR3","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0145-2126(09)70226-7","volume":"33","author":"SD Gore","year":"2009","unstructured":"Gore SD (2009) In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment? Leuk Res 33(Suppl 2):S2\u2013S6","journal-title":"Leuk Res"},{"key":"1090_CR4","doi-asserted-by":"crossref","unstructured":"List AF, Vardiman J, Issa JP, DeWitte TM (2004) Myelodysplastic syndromes. Hematol Am Soc Hematol Educ Program 297\u2013317.","DOI":"10.1182\/asheducation-2004.1.297"},{"key":"1090_CR5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2174\/156800907781662284","volume":"7","author":"ED Warlick","year":"2007","unstructured":"Warlick ED, Smith BD (2007) Myelodysplastic syndromes: review of pathophysiology and current novel treatment approaches. Curr Cancer Drug Targets 7:541\u2013558","journal-title":"Curr Cancer Drug Targets"},{"key":"1090_CR6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature02625","volume":"429","author":"G Egger","year":"2004","unstructured":"Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospect for epigenetic therapy. Nature 429:457\u2013463","journal-title":"Nature"},{"key":"1090_CR7","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood.V100.8.2957","volume":"100","author":"M Daskalakis","year":"2002","unstructured":"Daskalakis M, NguyenTT NC (2002) Demethylation of a hypermethylated p15\/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2\u2032deoxycytidine (decitabine) treatment. Blood 100:2957\u20132964","journal-title":"Blood"},{"key":"1090_CR8","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/CCO.0b013e328313699c","volume":"20","author":"G Garc\u00eda-Manero","year":"2008","unstructured":"Garc\u00eda-Manero G (2008) Demethylating agents in myeloid malignancies. Curr Opin Oncol 20:705\u2013710","journal-title":"Curr Opin Oncol"},{"issue":"4 Suppl 1","key":"1090_CR9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.exphem.2007.01.022","volume":"35","author":"RK Shadduck","year":"2007","unstructured":"Shadduck RK, Latsko JM, Rossetti JM, Haq B, Abdulhaq H (2007) Recent advances in myelodysplastic syndromes. Exp Hematol 35(4 Suppl 1):137\u2013143","journal-title":"Exp Hematol"},{"key":"1090_CR10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00277-008-0477-9","volume":"87","author":"A Kuendgen","year":"2008","unstructured":"Kuendgen A, L\u00fcbert M (2008) Current status of epigenetic treatment in myelodysplastic syndromes. Ann Hematol 87:601\u2013611","journal-title":"Ann Hematol"},{"key":"1090_CR11","first-page":"1596","volume":"9","author":"B Segura-Pacheco","year":"2003","unstructured":"Segura-Pacheco B, Trejo-Becerril C, P\u00e9rez-C\u00e1rdenas E et al (2003) Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res 9:1596\u20131603","journal-title":"Clin Cancer Res"},{"key":"1090_CR12","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00280-008-0773-z","volume":"63","author":"Y Song","year":"2009","unstructured":"Song Y, Zhang C (2009) Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression. Cancer Chemother Pharmacol 63:605\u2013613","journal-title":"Cancer Chemother Pharmacol"},{"key":"1090_CR13","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.yexcr.2008.03.001","volume":"314","author":"AY Law","year":"2008","unstructured":"Law AY, Lai KP, Ip CK, Wong AS, Wagner GF, Wong CK (2008) Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells. Exp Cell Res 314:1823\u20131830","journal-title":"Exp Cell Res"},{"key":"1090_CR14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000197911","volume":"30","author":"X Wang","year":"2008","unstructured":"Wang X, Chao L, Jin G, Ma G, Zang Y, Sun J (2008) Association between CpG island methylation of the WWOX gene and its expression in breast cancers. Tumor Biol 30:8\u201314","journal-title":"Tumor Biol"},{"key":"1090_CR15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-2407-5-44","volume":"5","author":"P Zambrano","year":"2005","unstructured":"Zambrano P, Segura-Pacheco B, P\u00e9rez-C\u00e1rdenas E et al (2005) A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer 5:44","journal-title":"BMC Cancer"},{"key":"1090_CR16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1475-2867-6-2","volume":"6","author":"A Ch\u00e1vez-Blanco","year":"2006","unstructured":"Ch\u00e1vez-Blanco A, Segura-Pacheco B, P\u00e9rez-C\u00e1rdenas E et al (2006) Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 6:2","journal-title":"Cancer Cell Int"},{"key":"1090_CR17","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10330-008-0119-7","volume":"7","author":"H Li","year":"2008","unstructured":"Li H, Chen S, Shu Y, Chen Y, Su Y, Wang X, Zou S (2008) Synergy of DNA methylation and histone deacetylase inhibitors in the re-expression of RASSF1A and P16 genes silenced in QBC cells. Chin-Ger J Clin Oncol 7:627\u2013630","journal-title":"Chin-Ger J Clin Oncol"},{"key":"1090_CR18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11684-009-0034-5","volume":"3","author":"H Li","year":"2009","unstructured":"Li H, Chen S, Shu Y, Chen Y, Su Y, Wang X, Zou S (2009) Effects of hydralazine and valproate on the expression of E-cadherin gene and the invasiveness and the invasiveness of QBC939 cells. Front Med China 3:153\u2013157","journal-title":"Front Med China"},{"key":"1090_CR19","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/annonc\/mdm204","volume":"18","author":"M Candelaria","year":"2007","unstructured":"Candelaria M, Gallardo-Rinc\u00f3n D, Arce C et al (2007) A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 18:1529\u20131538","journal-title":"Ann Oncol"},{"key":"1090_CR20","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1371\/journal.pone.0000098","volume":"1","author":"C Arce","year":"2006","unstructured":"Arce C, P\u00e9rez-Plasencia C, Gonz\u00e1lez-Fierro A et al (2006) A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS ONE 1:e98","journal-title":"PLoS ONE"},{"key":"1090_CR21","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","volume":"34","author":"A Due\u00f1as-Gonz\u00e1lez","year":"2008","unstructured":"Due\u00f1as-Gonz\u00e1lez A, Candelaria M, P\u00e9rez-Plascencia C, P\u00e9rez-C\u00e1rdenas E, de la Cruz-Hern\u00e1ndez E, Herrera LA (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34:206\u2013222","journal-title":"Cancer Treat Rev"},{"key":"1090_CR22","unstructured":"Candelaria M, Cetina L, P\u00e9rez-C\u00e1rdenas E et al (2010) Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer. Eur J Gynecol Oncol (in press)"},{"key":"1090_CR23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00045391-199501000-00011","volume":"2","author":"G Casta\u00f1eda-Hern\u00e1ndez","year":"1995","unstructured":"Casta\u00f1eda-Hern\u00e1ndez G, Falc\u00f3n-Neri A, Herrera-Abarca A, Herrera JE, Flores-Murrieta FJ (1995) Determination of three acetylator phenotypes in a Mexican population using sulfamethazine metabolic ratio. Am J Ther 2:57\u201360","journal-title":"Am J Ther"},{"key":"1090_CR24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM et al (2006) Clinical application and proposal for modification of the International Working Group (IWG) criteria in myelodysplasia. Blood 108:419\u2013425","journal-title":"Blood"},{"key":"1090_CR25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3324\/haematol.2009.010611","volume":"95","author":"R Gurion","year":"2010","unstructured":"Gurion R, Vidal L, Gafter-Gvili A, Belnik Y, Yeshurun M, Raanani P, Shpilberg O (2010) 5-Azacitidine prolongs overall survival in patients with myelodysplastic syndrome\u2014a systematic review and meta-analysis. Hematologica 95:303\u2013310","journal-title":"Hematologica"},{"key":"1090_CR26","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2003-12-4333","volume":"104","author":"A Kuendgen","year":"2004","unstructured":"Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R, Germing U, Gattermann N (2004) Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104:1266\u20131269","journal-title":"Blood"},{"key":"1090_CR27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.leukres.2004.11.022","volume":"29","author":"H Yang","year":"2005","unstructured":"Yang H, Hoshino K, S\u00e1nchez-Gonz\u00e1lez B et al (2005) Antileukemia activity of the combination of 5-aza-2\u2032deoxycytidine with valproic acid. Leuk Res 29:739\u2013748","journal-title":"Leuk Res"},{"key":"1090_CR28","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2006-03-009142","volume":"108","author":"G Garc\u00eda-Manero","year":"2006","unstructured":"Garc\u00eda-Manero G, Kantarjian HM, S\u00e1nchez-Gonz\u00e1lez B et al (2006) Phase 1\/2 study of the combination of 5\u2032aza-2-deoxycytidine with valproic acid in patients with leukemia. Blood 108:3271\u20133279","journal-title":"Blood"},{"key":"1090_CR29","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","volume":"110","author":"AO Soriano","year":"2007","unstructured":"Soriano AO, Yang H, Faderl S et al (2007) Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110:2302\u20132308","journal-title":"Blood"},{"key":"1090_CR30","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1200\/JCO.2006.09.4169","volume":"25","author":"W Blum","year":"2007","unstructured":"Blum W, Klisovic RB, Hackanson B et al (2007) Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 25:3884\u20133891","journal-title":"J Clin Oncol"},{"key":"1090_CR31","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1182\/blood.V112.11.3639.3639","volume":"12","author":"A Kuendgen","year":"2008","unstructured":"Kuendgen A, Bug G, Ottmann OG et al (2008) Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacitidine and valproic acid. Blood 12:3639","journal-title":"Blood"},{"key":"1090_CR32","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.V112.11.763.763","volume":"112","author":"E Raffoux","year":"2008","unstructured":"Raffoux E, de Labarthe A, Cras A et al (2008) Epigenetic therapy with 5-azacitidine, valproic acid and ATRA in patients with high-risk AML or MDS: results from the French VIVEDEP phase II study. Blood 112:763","journal-title":"Blood"},{"key":"1090_CR33","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1182\/blood.V112.11.945.945","volume":"12","author":"C Craddock","year":"2008","unstructured":"Craddock C, Goardon N, Griffiths M et al (2008) 5-Azacitidine in combination with valproic acid induces complete remissions in patients with advanced acute myeloid leukaemia but does not eradicate clonal leukaemic stem\/progenitor cells. Blood 12:945","journal-title":"Blood"},{"key":"1090_CR34","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1158\/1078-0432.CCR-09-0494","volume":"15","author":"MT Voso","year":"2009","unstructured":"Voso MT, Santini V, Finelli C et al (2009) Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 15:5002\u20135007","journal-title":"Clin Cancer Res"},{"key":"1090_CR35","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1038\/sj.onc.1211018","volume":"27","author":"A Jiemjit","year":"2008","unstructured":"Jiemjit A, Fandy TE, Carraway H, Bailey KA, Baylin S, Herman JG, Gore SD (2008) p21 (WAF1\/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. Oncogene 27:3615\u20133623","journal-title":"Oncogene"},{"key":"1090_CR36","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/ijc.24377","volume":"125","author":"C Nishioka","year":"2009","unstructured":"Nishioka C, Ikezoe T, Yang J, Komatsu N, Koeffler HP, Yokoyama A (2009) Blockade of MEK signaling potentiates 5-aza-2\u2032-deoxycytidine-induced apoptosis and upregulation of p21(waf1) in acute myelogenous leukemia cells. Int J Cancer 125:1168\u20131176","journal-title":"Int J Cancer"},{"key":"1090_CR37","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2009.23.4781","volume":"28","author":"L Shen","year":"2010","unstructured":"Shen L, Kantarjian H, Guo Y et al (2010) DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28:605\u2013613","journal-title":"J Clin Oncol"},{"key":"1090_CR38","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2009-02-203547","volume":"114","author":"TE Fandy","year":"2009","unstructured":"Fandy TE, Herman JG, Kerns P et al (2009) Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114:2764\u20132773","journal-title":"Blood"},{"key":"1090_CR39","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.bmc.2009.11.050","volume":"18","author":"D Kuck","year":"2010","unstructured":"Kuck D, Singh N, Lyko F, Medina-Franco JL (2010) Novel and selective DNA methyltransferase inhibitors: docking-based virtual screening and experimental evaluation. Bioorg Med Chem 18:822\u2013829","journal-title":"Bioorg Med Chem"},{"key":"1090_CR40","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1158\/1078-0432.CCR-07-1320","volume":"14","author":"RB Klisovic","year":"2008","unstructured":"Klisovic RB, Stock W, Cataland S et al (2008) A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res 14:2444\u20132449","journal-title":"Clin Cancer Res"},{"key":"1090_CR41","doi-asserted-by":"crossref","first-page":"657579","DOI":"10.1155\/2010\/657579","volume":"2010","author":"A Due\u00f1as-Gonz\u00e1lez","year":"2010","unstructured":"Due\u00f1as-Gonz\u00e1lez A, Vega MT, Mart\u00ednez-Ba\u00f1os D, Garc\u00eda-Hidalgo L, Sobrevilla P (2010) Response to hydralazine-valproate in a patient with mycosis fungoides. Case Report Med 2010:657579","journal-title":"Case Report Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-010-1090-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-010-1090-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-010-1090-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T10:09:44Z","timestamp":1591956584000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-010-1090-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,5]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["1090"],"URL":"https:\/\/doi.org\/10.1007\/s00277-010-1090-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,5]]}}}